Reflexology and bronchial asthma  by BRYGGE, T. et al.
Original Articles
Reflexology and bronchial asthma
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S. HEEGAARDk AND L. K. POULSEN*
*Allergy Unit National University Hospital, {Department of Orthopaedic Surgery, National University Hospital,
{Department of Biostatistics, and kEye Pathology Institute, University of Copenhagen, Denmark
Many asthma patients seek alternative or adjunctive therapies. One such modality is reflexology, whereby finger
pressure is applied to certain parts of the body. The aim of the study was to examine the popular claim that
reflexology treatment benefits bronchial asthma. Ten weeks of active or simulated (placebo) reflexology given by an
experienced reflexologist, were compared in an otherwise blind, controlled trial of 20þ20 outpatients with asthma.
Objective lung function tests (peak flow morning and evening, and weekly spirometry at the clinic) did not
change. Subjective scores (describing symptoms, b2-inhalations and quality of life) and also bronchial sensitivity to
histamine improved on both regimens, but no differences were found between groups receiving active or placebo
reflexology. However, a trend in favour of reflexology became significant when a supplementary analysis of
symptom diaries was carried out. It was accompanied by a significant pattern compatible with subconscious un-
blinding, in that patients tended to guess which treatment they had been receiving.
No evidence was found that reflexology has a specific effect on asthma beyond placebo influence.
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Many asthma patients seek alternative therapies such as
reflexology, homoeopathy and chiropractic manipulation
(1). Reflexology is a specific treatment whereby finger
pressure is applied to certain parts of the body, especially
the feet, but also other parts of the extremities and regions
on the back. It is claimed that a large number of diseases
can be treated, but no anatomical or physiological
mechanism of action has been described. Among asthma
patients, reflexology is a well-known alternative or com-
plementary treatment, and casuistic reports about a positive
effect are known among patients. However, the effect has so
far never been documented. On the contrary, one rando-
mized, controlled clinical trial failed to demonstrate
significant differences in symptom and medication scores
or lung function between a control group and a reflexology-
treated group, whereas a marked improvement was
observed during the study for both groups (2). Since
asthma is characterized by asymptomatic periods amongst
periods with symptoms, spontaneous improvement as well
as outright placebo effects are expected (3). Consequently,Received 20 September 2000 and accepted 4 October 2000.
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0954-6111/01/030173+07 $35?00/0controlled investigations are mandatory. A randomized,
double-blind, controlled trial was designed, comparing active
with simulated (placebo) reflexology, with the aim to study
its effect on bronchial asthma assessed by clinical symptoms,
medicine intake, objective lung function parameters, bron-
chial sensitivity and quality-of-life questionnaires.
Materials and methods
SUBJECTS
Forty patients aged 18–60 years with a forced expiratory
volume in 1 sec (FEV1) greater than 60% of the predicted
value were included. The asthma diagnosis was established
by an increase in FEV1 of more than 15% after inhalation
of a b2-agonist, and/or airway hyper-responsiveness to
histamine defined as a 20% decrease in FEV1 after
inhalation of a histamine concentration (PC20 for hista-
mine) of no more than 2mgml71. Patients used short-
acting b2-agonists and were allowed to use inhaled steroids
less than 2000 mg per day if the dose was constant for more
than 4 weeks prior to the study and during the trial,
whereas no systemic steroids were allowed 6 weeks prior to
the study. No other anti-asthmatic treatment was allowed.
Subjects were excluded if they experienced airway infections
during a 6-week period before the study started. Patients
with interfering seasonal asthma were likewise excluded, as
were patients who could not co-operate or suffered from# 2001 HARCOURT PUBLISHERS LTD
baseline, 10 weeks of treatment and 2 weeks post-treatment
(Fig. 1).
FIG. 1. Study flow chart. T¼treatment-session. * Indicates
that the test was performed once; **indicates that the test
was performed before and after treatment session. Week
X follows visit X.
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to interfere with the investigation. Finally, pregnancy or
planned pregnancy was an exclusion criterion. All patients
had two feet and a normal peripheral neurological status.
Drop-out was defined as hospitalization or marked changes
in regular medication as well as withdrawal of informed
consent. The study was approved by the local Ethical
Review Committee for Copenhagen and Frederiksberg and
complied with the Helsinki 2 Declaration. Patients were
included only after informed consent.
DESIGN
The trial was randomized, double-blinded, and placebo-
controlled. After 2 weeks of baseline registration of
symptom and medication score (see section on diary cards)
a total score of at least 7 points per week was mandatory
for inclusion. Asthma severity was graded as either low:
7–14 points per week, or high: 15 points or more. The
patients were then randomized to receive either simulated
(placebo) (n¼20) or active reflexology (n¼20) by a
computer-generated ‘minimization’ method (4), taking
gender and severity of disease into account. The randomi-
zation code was given only to the reflexologist in separate,
sealed envelopes for each patient by a technician otherwise
not involved in the study. After all 10-weekly treatments,
the patients were asked to guess which treatment they
thought they had received (active, placebo or ‘don’t know’)
in order to assess the ecacy of the blinding.
REFLEXOLOGY REGIMEN
All patients received 10 treatments of 45 min once a week
by the same qualified, trained reflexologist in a specially
allocated room at the Allergy Unit. The patients were
treated in an almost supine position in a designated chair.
Special areas of planta pedis bilaterally were treated for
approximately 2 min at each point. Then, with the patient
prone, pressure was applied at special points on the
extremities and back. Then the patients returned to the
chair, where a relaxation technique was applied lasting
approximately 10min. Simulated reflexology was given in a
similar way using ‘placebo’ areas on the feet, extremities
and backs, the active areas being avoided.
DIARY CARDS
The patients kept diary cards throughout the whole
investigation (Fig. 1), recording: self-measured peak flows,
the best of three measurements (Mini Wright Peak Flow
Meter, Airmed, Harlow, U.K.) and symptom score on a
scale of 0 (no symptoms) to 4 (worst symptoms), as well as
b2-agonist use when necessary. Data were recorded in the
morning immediately after getting up and in the evening.
The diary cards were checked and replaced at each visit. In
the first week of the pretreatment period, patients were
trained how to complete the diary cards and measure peak
flow: thereafter registration was made during 2 weeks ofLUNG FUNCTION MEASUREMENTS AND
BRONCHIAL HISTAMINE CHALLENGE
TEST
Forced expiratory volume in 1 sec and forced vital capacity
(FVC) were recorded at each study visit, according to Fig. 1.
At visits one, five and 10 the lung function was measured
not only before, but also after, reflexology in order to assess
any immediate effect. Percentages of predicted values (5)
were used in the calculations.
Bronchial sensitivity was measured as PC20 for histamine
before reflexology treatments started and 1 week after the
last treatment (Fig. 1) according to Cockroft (6). Short-
acting b2-agonists were withheld for 6 h prior to testing;
inhaled steroids were not withheld.
QUALITY OF LIFE
Quality of life was assessed before and after the treatment
period by a standardized questionnaire, SF-36 (7). The
questionnaire was scored according to the guidelines (8),
results being expressed on the eight standard SF-36 scales.
ANALYSIS OF DATA
Patients’ daily registration of symptoms, medication, and
morning peak flow 7 days before the first treatment
(baseline week) and 7 days after each of the 10 treatments
were used for the calculation of a daily mean for that week.
Depending on the variable, the individual response of a
patient was calculated relatively [(Xafter7Xbefore)/Xbefore] or
absolutely [(Xafter7Xbefore)], or ‘semi-relatively’ [(Xafter7
Xbefore)/1/2(

X
p
before þ

X
p
after) ¼ 2(

X
p
after 7

X
p
before)].
Analyses in terms of relative change are substantially
influenced by those with low scores (due to division by
near-zero), whereas analyses in terms of absolute changes
can be dominated by only few ‘dramatic’ symptom or
medication scores. The semi-relative change represents the
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portrays the change of the square root value. It is deployed
here in an effort to equalize responsiveness over the
spectrum of severities.
Where the patient’s guess as to treatment arm is
subjected to a trend test or used as an outcome predictor,
‘don’t know’ is treated as located midway between ‘active’
or ‘placebo’. Paired, unpaired, and regression-type t-tests
are used as appropriate. Tests with two-sided, P-values
55% are reported as significant, explicit P-values being
reserved for key comparisons.
Results
Twenty patients were randomized to active treatment: 12
women and eight men (mean age 39?0 years, range 22–56),
and 20 patients to simulated reflexology: 13 women and
seven men (mean age 38?3 years, range 24–54). Four
patients with low and 16 with high symptom medication
scores were allocated to both treatment groups. All patients
completed the study and received the planned 10 treat-
ments. The treatment period, 63 days in case of perfect
compliance, was on average 71?4 days (range 63–105) for
the actively-treated, and 73?5 days (range 63–77) for the
placebo-treated group. Mainly due to vacations, the
interval between two treatments exceeded 2 weeks for five
actively-treated and two placebo patients, once each, in the
course of the 400 treatments.
SYMPTOM AND MEDICATION SCORES
As some patients needed more than 1 week for training
their diary registration, only the last baseline week, where
all patients has filled in diaries, was used for calculations.
For this reason, a few of the included patients have a ‘0’
registration for either symptom or medication score the last
week before treatment.
Patients’ weekly average symptom and medication scores
(number of puffs of b2-agonist) were used, as displayed in
Fig. 2. Relative changes in symptom and medication scores
showed a statistically significant decrease after treatment,
visit 10, compared to baseline values, visit 0, in both groups
(Fig. 3). However, no statistically difference between the
groups was observed.
PEAK FLOW REGISTRATIONS
Weekly averages of morning peak-flow registrations during
the study are shown in Fig. 2. The relative change after
treatment compared to baseline is illustrated in Fig. 3. A
small increase after treatment is found in both treatment
groups [actively-treated: median þ0?8% (range716?7% to
þ40?2%); placebo-treated: median þ4?4% (716?8% to
þ21?0%)]. However, these changes are not significant,
neither when tested as absolute values nor as relative
changes. Similarly, evening peak-flows showed small and
non-significant fluctuations [actively-treated: median
70?6% (range 714?0% to þ25?7%); placebo-treated:median þ0?5% (range 710?6% to þ24?3%)]. No signifi-
cant differences between the two groups exist.
LUNG FUNCTION MEASUREMENTS AND
BRONCHIAL HISTAMINE CHALLENGE
TEST
The weekly FEV1 used are included in Fig. 2. No
statistically significant changes in FEV1 or FVC were
observed during the study, either within or between the
groups. Similarly, the FEV1/FVC ratio showed no sig-
nificant changes during the study [active group: median
70?4% (range 722?4% to þ31?7%); placebo group:
median þ2?7% (range 714?4% to 12?3%)] and no
significant group differences were observed. Measurement
of FEV1 before and after treatment sessions showed no
significant immediate effect of reflexology at any visit, either
within or between the groups. PC20 histamine was some-
what higher before treatment in the placebo group than in
the active group (Fig. 4). Within both groups, PC20 for
histamine increased significantly during treatment. The
relative improvement did not reach a statistically significant
difference between the two groups (t-test on the logarithmic
scale employed in Fig. 4).
QUALITY-OF-LIFE QUESTIONNAIRES
The patients’ responses to the SF-36 questionnaire were
transformed according to the instructions provided by the
developer of the questionnaires (8), producing eight
dimensions (physical functioning, role limitations due to
physical problems, bodily pain, general health perception,
vitality, social functioning, role limitations due to emo-
tional problems and general mental health) where quality of
life is expressed on a scale from 0 to 100%, the latter
representing the optimal situation. All but three patients
(who happened to be placebo cases) produced pre- and
post-questionnaires. In general, almost all the parameters in
both groups improved throughout the study. The active
group improved significantly on the dimensions: physical
function, (lack of) physical limitations, and vitality,
whereas the placebo group only improved on (lack of)
physical limitations. Three dimensions showed group
inequalities after and, in part, before treatment, but when
improvements i.e. before–after differences, were compared,
no significant differences between the two groups was
detected on any of the eight scales.
SUPPLEMENTARY ANALYSIS
In order to overcome the risk of making a type 2 error and
investigate a possible borderline effect of the treatment,
several data transformations were tried. A preliminary
analysis made it clear that no transformations could change
the results of the objective parameters, so only symptoms
and medication scores are reported. In order to reduce the
dispersion in symptom and medication data, the last 3,
apparently stable, weeks of the study were aggregated and
FIG. 2. Individual courses of FEV1 and the three diary variables [weekly means of symptom score (symptoms), number of
puffs of b2-agonist (medication) and morning peak flow (PEF AM)]. Week 0 is the baseline week succeeded by the 10 weeks
following each of the 10 reflexology sessions.
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FIG. 3. Relative changes in three diary variables [weekly
means of symptom score, numbers of puffs of b2-agonist
(medication score) and morning peak flow (PEF AM)].
*: active treatment; ^: placebo. The week after the last
treatment is plotted as change relative to baseline week.
Three patients marked with black squares in the middle
panel took zero medication both in week 0 and in week
10. In both groups, the symptom and medication scores
but not the peak flow improved significantly, but no
significant differences were found between the groups, in
terms of either absolute or relative change.
FIG. 4. Histamine sensitivity in the active group (*) and
the placebo group (^) before and after the 10 treatments
of reflexology. When 16 mg ml71 failed to induce420%
drop in FEV1, 16mgml
71 has been marked in the figure.
Geometric means are marked in bold. Within both groups
a significant improvement occurred. The placebo group
had slightly higher levels than the active group, but the
relative improvement showed no significant difference
between the two groups.
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analysis of symptom and medication data was performed
for the reasons stated in the Methods section. Additionally,
calculations excluding patients with intervals between two
treatments exceeding 2 weeks (five actively-treated and two
placebo patients), leaving a total of n¼33, were performed.
Table 1 summarizes the analyses in terms of P-values. For
the medication scores, all transformations maintain the
difference between the groups as non-significant, whereas
the symptoms do appear to have a favourable association
with reflexology treatment, although the single very low P-
value cannot be taken on face value as it must be regarded
as the result of repeated probing into the data set.
THE PATIENT’S GUESS
In the actively-treated group 12 patients guessed that they
had received active reflexology, six simulated treatment and
two did not know. Among the placebo-treated patients,
nine patients guessed that they had received placebo
treatment, two active treatment and nine did not know.
Participants’ guesses thus did not seem to have a
preferential direction (despite the fact that nearly everyone
improved), but a clear tendency towards correctly guessing
the treatment received was apparent [(trend)¼2?20, two-
sided P¼2?8%]. When the guess variable is introduced, the
P-values generally increase (Table 1) and only in the semi-
relative transformation of symptom scores a significant
difference between the active and placebo group remains.
TABLE 1. Stastical differences (P-values in %) between active and placebo groups regarding symptom and medication scores
using different transformations of data
All 40 patients 33 patients with uninterrupted compliance
Week 10 Weeks 8–10 Week 10 Weeks 8–10
SS MS SS MS SS MS SS MS
Absolute change 5?8 21 5?2 14 1?7 6?2 3?0 12
Adjusted for guess 11 34 12 34 10 26 17 49
Semi-relative change 1?9 7?7 4?6 15 0?46 7?4 3?4 30
Adjusted for guess 3?5 14 10 36 2?7 21 16 83
SS: symptom score; MS: median score.
Supplementary analyses of symptom and medication scores using absolute changes and semi-relative changes from pre-
treatment week to post-treatment. Post-treatment values are used either the week after final treatment (week 10) or aggregated
data for the last 3 weeks of the study (weeks 8–10). The right part of the table shows the analogous results after exclusion of
seven participants whose treatment intervals on one occasion exceeded 2 weeks. Two-sided student P-values are shown as %;
all changes favour reflexology. The same parameters are shown with adjustment for the participant’s guess as to regimen.
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This placebo-controlled study of the effect of reflexology in
bronchial asthma showed a decrease after treatment in the
subjective parameters symptom score and asthma self-
medication regardless of placebo or active reflexology
treatment, but when the data were analysed according to
our original protocol no significant differences were found
between the groups. The patients’ quality-of-life assess-
ments showed some increased scores after treatment, but
again no difference was found between the groups. The
improvement in the subjective parameters was not sup-
ported by objective lung function tests. Bronchial sensitivity
decreased significantly for both groups and once again
without a treatment difference, perhaps because of better
compliance with anti-inflammatory drugs under trial
conditions. From this, it was concluded that this study
did not show an effect of reflexology as adjunctive
treatment to adult patients with bronchial asthma.
A larger study would have had more power to do so. In
retrospect, an effect on the symptom score that reduced it
from 1?8 (the observed average on the 0–4 scale) to 0?3 on
active treatment and to 1?6 on placebo would have enjoyed
a power of 80%. The observed active–placebo gap was only
two-thirds of that. Corresponding figures for b2-agonist
administration might be: 2?6, 0?5, 1?6 puffs day71, 80% and
one-half respectively.
As the planned analysis of the self-reported asthma
medication and symptom-scores (and not lung function
data) showed an effect for both groups, it was decided to
take another look at these data, in order not to overlook a
possible effect of the treatment. In the extended analysis
three transformations were used and a significant difference
in favour of the actively-treated group was shown for
symptom scores, but not self-medication. This trend was
most prominent when looking at the groups of patients
with uninterrupted compliance. Self-reported symptoms are‘soft’ data and may depend on the patient’s belief in active
or placebo treatment. Unconscious signals from the
reflexologist may have influenced susceptible individuals.
In this way, a certain un-blinding may have taken place,
and this was supported by the finding of a clear tendency
for the participants to make correct guesses. The results
were corrected for guesses, which weakened most of the
significance levels (only semi-relative change at the 10-week
registration now showed a significant change at 5% level).
Unfortunately, this pattern is open to opposite casual
interpretations: either un-blinding leads to subjective
convictions that cause reinforced placebo effects (and of
course, correct guesses); or a genuine effect induces in a
number of correct guesses (in addition to being reflected in
favourable symptom scores).
Although the authors believe that the semi-relative
transformation is a valid compromise between absolute
and relative comparisons, and that it reduces the undesir-
able influence of extreme data, it must be emphasized that
to the author’s knowledge, this transformation has not
previously been used in data evaluation in asthma trials.
Thus, by the standards normally used in clinical trials and
according to the data analysis stipulated in the current
study’s original protocol, it cannot be concluded that the
study showed an effect of active reflexology better than
placebo. The results address, however, the need for further
studies of the relation between reflexology and the
subjective feeling of improvements experienced by some
patients. A more rigorous blinding should be ensured in
further such studies, perhaps by breaking the close
psychological contact between patient and therapist.
Even though reflexology is widely used as adjunctive
treatment, the authors are only aware of one controlled
clinical trial using reflexology in bronchial asthma (2). In
that study, 30 patients were randomized to receive
10-weekly treatment sessions of reflexology or to a
control group who did not receive placebo reflexology. A
REFLEXOLOGY AND ASTHMA 179favourable course was demonstrated in both groups, but no
effect could be ascribed to reflexology treatment.
Other forms of alternative therapy of asthma have been
described (9,10). Chiropractic treatment for asthma has
recently been investigated (11). In a randomized, controlled
study, 80 children received either active or simulated
chiropractic manipulation. A substantial improvement in
symptoms and quality of life, and a reduction in b2-agonist
use was observed, but these changes did not differ
significantly between the active and placebo groups. No
significant changes in objective measurements of airway
function were found. In the study mentioned 11 chiroprac-
tors participated, and the patients were allowed some
latitude due to illness or vacations, but each subject was
required to receive between 20 and 36 treatments during the
4-month study.
In the present study fewer patients participated, but all
were treated by the same therapist, and all received 10
treatments within, on average, 71 days and 74 days for the
two groups, respectively. Even with this strict protocol
good compliance was achieved, but subsequent to termina-
tion of the study, the reflexologist who took part in
scheduling the sessions objected that this degree of
compliance was not sucient. For this reason further
analyses were performed in which seven patients with
interrupted regimens were omitted. Due to vacations etc., a
schedule like the one originally stipulated may be dicult to
comply with in everyday life, but post hoc exclusions always
should be avoided: it is impossible to tell whether the
cleaned-up data set is more trustworthy.
In the light of the weak trend for a difference in symptom
scores a larger patient sample would have been preferable.
The number of patients in the present study may be too low,
but if an increase leads to the inclusion of more therapists or
longer study period new elements of variance and perhaps a
lower compliance may be introduced. On the other hand, if
an effect did exist, it should be possible to show it with the
number of patients enrolled, judging from published clinical
trials with other forms of anti-asthmatic medication (12,13).
Thus, from a clinical point of view, the present study has
failed to demonstrate that active reflexology compared with
placebo reflexology has a relevant clinical effect on
bronchial asthma.
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